Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China; State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, CAS Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China.
State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, CAS Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China; Cancer Center, Shanghai Tenth People's Hospital, Tongji University, School of Medicine, Shanghai 200072, China.
Cell Rep. 2020 Sep 15;32(11):108158. doi: 10.1016/j.celrep.2020.108158.
The traditional Chinese medicinal herb Notopterygium incisum Ting ex H.T. Chang has anti-rheumatism activity, and a mass spectrometry assay of patients' serum after administration of the herb revealed that notopterol is the most abundant component enriched. However, the functions of notopterol and its molecular target in rheumatoid arthritis (RA) treatment remain unknown. Here, we show in different RA mouse strains that both oral and intraperitoneal administration of notopterol result in significant therapeutic effects. Mechanistically, notopterol directly binds Janus kinase (JAK)2 and JAK3 kinase domains to inhibit JAK/signal transducers and activators of transcription (JAK-STAT) activation, leading to reduced production of inflammatory cytokines and chemokines. Critically, combination therapy using both notopterol and tumor necrosis factor (TNF) blocker results in enhanced therapeutic effects compared to using TNF blocker alone. We demonstrate that notopterol ameliorates RA pathology by targeting JAK-STAT signaling, raising the possibility that notopterol could be effective in treating other diseases characterized by aberrant JAK-STAT signaling pathway.
中药羌活具有抗风湿作用,对服用该药的患者血清进行质谱分析显示,异欧前胡素是最丰富的富集成分。然而,羌活醇及其在类风湿关节炎(RA)治疗中的分子靶点的功能仍不清楚。在这里,我们在不同的 RA 小鼠品系中表明,羌活醇的口服和腹腔给药均具有显著的治疗效果。从机制上讲,羌活醇直接结合 Janus 激酶(JAK)2 和 JAK3 激酶结构域,抑制 JAK/信号转导和转录激活因子(JAK-STAT)激活,导致炎症细胞因子和趋化因子的产生减少。至关重要的是,与单独使用 TNF 阻滞剂相比,使用羌活醇和 TNF 阻滞剂的联合治疗可产生增强的治疗效果。我们证明羌活醇通过靶向 JAK-STAT 信号通路改善 RA 病理,这表明羌活醇可能对治疗其他以异常 JAK-STAT 信号通路为特征的疾病有效。